Universiteit Gent

Vib Vzw

Research Corporation Technologies, Inc.

Vrije Universiteit Brussel

Vib Vzm

Wetenschappelijk Instituut Volksgezondheid

Nico Callewaert

Sven Eyckerman

Simon Devos

Francis Santens

Bram Laukens

Loes Van Schie

Wander Van Breedam

Toon Laeremans

Jan Steyaert

Els Pardon

Mouna Guerfal

Steven Geysens

Leander Meuris

Joris Delanghe

Petra Sophie Tiels

Kristof Vandewalle

Anna Depicker

Katrien Claes

Karen De Pourcq

Elisabeth Van Aken

Vikram Virdi

Tom Raes

Anjana Batni

Nele Festjens

Christiane Huygen

Kristof De Schutter

Yao-Cheng Lin

Wim Nerinckx

Andries De Koker

Robin Vanluchene

Dieter Vanderschaeghe

The present invention relates to the field of biochemistry, more particularly to proteomics, more particularly to protein sequencing, even more particularly to single molecule peptide sequencing. The invention discloses methods for single molecule protein sequencing and/or amino acid identification using cleavage inducing agents which are not specific for one particular amino acid, cleave polypeptides step by step from the N-terminus onwards and provide information on the identity of the cleaved amino acids based on the reaction kinetics.

Means and methods for single molecule peptide sequencing

The present invention provides means and methods for the production in eukaryotic cells of homogeneous forms of small glycan structures which carry terminal galactose residues. In addition, the invention provides glycan-conjugates based on specific coupling with galactose residues present on the recombinant glycoproteins.

Genetically engineered eukaryotic cells producing LacNAc-glycoproteins

The present invention relates to the field of biochemistry, more particularly to proteomics, more particularly to protein sequencing, even more particularly to single molecule peptide sequencing. The invention discloses methods for single molecule protein sequencing and/or amino acid identification using cleavage inducing agents which are not specific for one particular amino acid, cleave polypeptides step by step from the N-terminus onwards and provide information on the identity of the cleaved amino acids based on the kinetics.

The present invention relates to the field of recombinant protein production in a host cell. More specifically the invention relates to the field of oral protein delivery. Specifically, the invention provides oral pharmaceutical formulations comprising the culture medium of a recombinant host secreting a recombinant protein. The resulting oral pharmaceutical formulations are useful for the treatment of gastro-intestinal and/or buccal disorders. Additionally, the oral pharmaceutical formulations are useful for prophylactic and vaccine purposes.

Means and methods for oral protein delivery

The present invention provides nucleotide sequences encoding polypeptides comprising immunoglobulin variable domains with engineered glycosylation acceptor sites. Specifically, the invention provides immunoglobulin variable domain proteins modified with selected glycans and specific glycan-conjugates thereof. Also provided herein are methods for the production of glycosylated immunoglobulin variable domains and glycan-conjugates thereof.

Glycosylation of variable immunoglobulin domains

A non-surgical treatment of cataract in a human or animal. The invention specifically relates to the administration of a deglycating enzyme and its cofactor(s), which results in the deglycation of the lens crystallins. The disclosure thus relates to a minimal invasive type of treatment of cataract, which is easier and cheaper compared to existing surgical methods.

Compositions for use to treat cataract

The present application relates to the field of glyco-engineering and, more specifically, to eukaryotic cells wherein both an endoglucosaminidase is present and made deficient in UDP-galactose 4-epimerase (GalE). Typically, a glycoprotein is also present in the cells. These cells can be used to deglycosylate or partly deglycosylate the (exogenous) glycoprotein, in particular, without the need for adding an extra enzyme. Methods are also provided for the application of these cells in protein production.

Cells producing glycoproteins having altered N- and O-glycosylation patterns and methods and use thereof

The present invention provides methods and kits for preparing a collection of degraded DNA fragments isolated from a biofluid sample of an individual. The prepared collection of nucleic acid sequences can be used in a diagnostic method such as for example detection and/or prognosis of cancer.

Means and methods for amplifying nucleotide sequences

The disclosure relates cells or cellular systems that express both a membrane protein and a binding domain directed to the membrane protein. Also, methods are provided that use such cells or cellular systems to produce higher amounts of the membrane proteins. Further, the cells or cellular systems can be used as tools for the structural and functional characterization of membrane proteins, as well as for screening and drug discovery efforts targeting membrane proteins.

Tools and methods for expression of membrane proteins

(TB) is a major health problem and currently, the only licensed TB vaccine isBacille Calmette-Guerin (BCG). In the present invention, mutation of mycobacterial components reportedly involved in phagosome maturation inhibition was evaluated for vaccine purposes, as such mutations should result in better vaccine antigen processing and presentation. Thus, BCG mutants in genes coding for ManLAM capping &#x3b1;-1,2-mannosyltransferases and the PI3P phosphatase SapM were evaluated as TB vaccines in a stringent mouse model. Vaccination with both ManLAM capping mutants and the SapM mutant resulted in significantly longer survival as compared to non-vaccinated mice, whereas vaccination with the parental BCG did not. Moreover, mice vaccinated with the SapM mutant survived significantly longer than mice vaccinated with the parental BCG. The mutant BCG strains showed unaltered phagocytosis, replication, lysosome colocalization and oxidant activity in macrophages and similarly induced autophagy in the latter. Additionally, replication and granuloma formation in mice was unaffected, indicating BCG-equivalent safety of these vaccines.

Mycobacterium mutants for vaccines with improved protective efficacy

The present invention provides the genome sequence ofand manually curated annotation of protein-coding genes. The invention provides novel nucleic acids, proteins, and related expression vectors useful for genetic engineering of methylotrophic yeast strains, as well as engineered methylotrophic yeast strains particularly, and use thereof for recombinant production of heterologous proteins including glycoproteins suitable for use in mammals including humans.

[object Object]

Growing community of inventors

Nevele, Belgium

Nico Callewaert